Background. We previously reported that preformed anti-MHC class I-related chain A (MICA) antibodies increase the risk for renal graft rejection and enhance the deleterious effect of PRA + status early after transplantation. Methods. We studied 727 kidney recipients. Days to reach optimal serum creatinine level, estimated glomerular filtration rate (eGFR) at Month 3 and chronic kidney disease (CKD) stages were recorded. Anti-MICA specificities and C1q binding were tested by solid-phase assay. Complement-dependent cytotoxicity (CDC) and flow cytometry (FC) cross-matches with HeLa and PMA/CD28-T-blasts were performed. Results. PRA + MICA + recipients exhibited longer time to reach optimal serum creatinine level after transplantation (P = 0.005) and had the lowest eGFR at Month 3 (P = 0.006). PRA + MICA
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Background. We previously reported that preformed anti-MHC class I-related chain A (MICA) antibodies increase the risk for renal graft rejection and enhance the deleterious effect of PRA + status early after transplantation. Methods. We studied 727 kidney recipients. Days to reach optimal serum creatinine level, estimated glomerular filtration rate (eGFR) at Month 3 and chronic kidney disease (CKD) stages were recorded. Anti-MICA specificities and C1q binding were tested by solid-phase assay. Complement-dependent cytotoxicity (CDC) and flow cytometry (FC) cross-matches with HeLa and PMA/CD28-T-blasts were performed. Results. PRA + MICA + recipients exhibited longer time to reach optimal serum creatinine level after transplantation (P = 0.005) and had the lowest eGFR at Month 3 (P = 0.006 sera, P = 0.0006). Anti-AYVE supereplet reactivity was significantly higher in HLA + MICA + versus HLA − MICA + patients (P < 0.001) and significantly superior than anti-CMGWS supereplet within HLA + MICA + patients (P = 0.001). Three of 13 anti-MICA + pre-transplant sera were positive for the C1q binding assay; one of them (serum 3) exclusively recognized AYVE supereplet with a strong reactivity against MICA*027 antigen (same as MICA*008). Anti-MICA antibodies in anti-HLA-absorbed serum 3 bound native MICA molecules in MICA*008 + HeLa and PMA/CD28-T-blasts and mediated cell death by activating complement. Conclusion. Preformed anti-MICA antibodies may occasionally be cytotoxic by fixing and activating complement. This way they might contribute to worse early kidney graft function.
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I N T RO D U C T I O N
The role of MHC class I-related chain A (MICA) polymorphic proteins in alloresponse has been increasingly recognized. MICA products are constitutively present in endothelial cells, and its expression increases in other renal compartments after stress accompanying transplantation [1] . MICA-driven deleterious immune response against grafts may be mediated by the activation of cytotoxic cells through engagement of NKG2D receptor [2] . Additionally, anti-MICA antibodies show the capacity to trigger complement-dependent or FcγR-dependent the cytotoxicity and/or the capacity to activate endothelia and promote thrombosis [3] .
Zwirner et al. [4] found anti-MICA antibodies for the first time in sera of transplanted patients after rejection. Later studies showed a relationship between pre-or post-transplant anti-MICA antibodies and kidney allograft loss [5, 6] , dysfunction and acute rejection [7] . Serial long-term follow-ups [8, 9] [10] . Anti-MICA antibodies have been correlated with C4d-positive rejections [11, 12] , and they have been shown to mediate complement-dependent cytotoxicity in kidney microvascular endothelial cells, HeLa or MICA-transfected cells [5, 13, 14] . However, lymphocytes do not express MICA, and cytotoxic anti-MICA antibodies cannot be detected by traditional complementdependent cytotoxicity (CDC). This fact has made it difficult to systematically analyse the contribution of anti-MICA antibodies complement fixation capacity to graft deterioration.
Here, we further delineate the impact of preformed anti-MICA antibodies in kidney allograft function and analyse the anti-MICA specificities. We demonstrate that pre-transplant serum anti-MICA antibodies can bind native MICA molecules on cell membranes. By using both the C1q single-antigen beads assay and CDC, we show that these antibodies are able to mediate cell death by fixing and activating the complement cascade.
M AT E R I A L S A N D M E T H O D S

Patients and samples
We retrospectively analysed 727 consecutive kidney allograft recipients transplanted between 2005 and 2011 in our hospital (cohort previously described [10] ). The study was performed under informed consent and approved by the institutional review board (reference 10/014). Pre-transplantation sera were collected the day of transplantation. Allograft function was compared among patients categorized into four groups according to PRA status and flow cytometry (FC 
HLA and MICA genotyping
Blood donor DNA samples were typed by LABType ® SSO HLA-A, HLA-B, HLA-DR and MICA and analysed by Luminex (One Lambda). HeLa HLA-A, -B and -C and blood donor HLA-C were analysed by PCR-SSO using INNO-LiPA kits and LiRAS® software (Innogenetics). Figure 1 shows a flow chart of main analysis in our population.
CD3
+ T lymphocyte isolation, induction of MICA expression and FC CD3 + T cells sorted from healthy donors' PBMCs (CD3 MicroBeads, MACS Miltenyi Biotec, San Diego, CA, USA) were resuspended in culture medium plus IL-2, PMA and anti-CD28 [16] . HeLa cells or PMA/CD28-T-blasts were incubated with MICA/B, isotype control and anti-HLA MoAbs (BD Biosciences, San Jose, CA, USA). For cross-matches, cells were first incubated with anti-MICA-positive sera followed by anti-human IgG-FITC (MACS Miltenyi Biotec). FC was analysed using a Navios™ Flow Cytometer (Beckman Coulter, Brea, CA, USA).
Complement-dependent cytotoxicity PMA/CD28-T-blasts were incubated in Terasaki plates with recipient serum and goat anti-human IgG antiserum (AHG, Sigma-Aldrich, St Louis, MO, USA), followed by rabbit complement. After staining with 5 μL of FluoroQuench™ (One Lambda), cell mortality was examined by fluorescence microscopy.
Statistical analysis
Frequencies were compared by Fisher's or Pearson chisquare tests and means were analysed by Student's t-test or oneway ANOVA. Cox regression was performed in the univariate analysis to obtain the HR for clinically relevant covariables. Variables with a P-value <0.100 were introduced in the multivariate model to assess their independent effect. P-values <0.05 was considered significant. SPSS (version 18.0; IBM, Armonk, NY, USA) and MedCalc (version 11.4.2.0; MedCalc Software, Ostend, Belgium) were used for statistical analysis.
R E S U LT S
Pre-transplant PRA + MICA + status is associated with decreased eGFR, longer time to reach optimal serum creatinine levels and the highest risk for CKD stage 5 in the early post-transplantation period In the analysed cohort, anti-MICA-positive and -negative patient subgroups showed no statistically significant differences
O R I G I N A L A R T I C L E
C y t o t o x i c a n t i -M I C A a n t i b o d i e s i n t r a n s p l a n t regarding sex and age of donor and recipient, donor type, immunosuppressive treatments and original disease [10] .
We previously observed that pre-transplant PRA + MICA + sensitization significantly decreased allograft survival and was associated with more biopsy-proven rejection [10] . To further analyse how preformed anti-MICA antibodies enhanced the deleterious effect of PRA + status on allograft function, the number of days to reach optimal serum creatinine levels and eGFR at post-transplant Month 
MICA
+ 79.47 ± 25.94 days; P = 0.005). Interestingly, the PRA + groups were similar regarding the percentage of highly immunized (PRA >50%) patients and frequency of anti-HLA class I and/or class II antibodies as recorded by Luminex (no significant differences; Figure 2 ). However, we noticed that PRA + MICA − patients showed the highest eGFR ( Figure 2A ) and reached optimal creatinine levels earlier than the remaining groups ( Figure 2B ). This could be explained by differences in immunosuppressive treatment since more PRA (Table 1) . Remarkably, coexistence of anti-HLA and anti-MICA antibodies emerged as an independent risk factor for CKD5T compared with PRA − MICA − (HR 4.92, P = 0.030) in the multivariate analysis. Donor age (71-85 years) was also independently associated with a higher risk for CKD5T (HR 3.34, P = 0.028).
Preformed anti-MICA antibodies are polyspecific and show stronger reactions when coexisting with anti-HLA antibodies Among our pre-transplant anti-MICA-sensitized recipients (n = 52), 48% showed a positive anti-MICA single-antigen study (n = 25). Anti-HLA were present together with anti-MICA antibodies in 12 of these patients (HLA + MICA + ) whereas 13 subjects had isolated anti-MICA antibodies (HLA − MICA + ). Preformed anti-MICA antibodies were mostly polyspecific, with a mean of five different specificities per serum in both groups ( Figure 3A) . Antibodies against MICA*001 were the most frequent, followed by anti-MICA*018 (64 and 60% of patients, respectively). Those specificities were more prevalent in patients without HLA immunization versus double-immunized patients (69 versus 58% and 69 versus 50%, respectively). Among 
O R I G I N A L A R T I C L E
C y t o t o x i c a n t i -M I C A a n t i b o d i e s i n t r a n s p l a n t After transplantation, the MICA genotype was available in 17 donors. Preformed anti-MICA antibodies were donor specific in nine patients (anti-MICA DSA, sera 2, 3, 5, 6, 9, 13, 14, 16 and 17) and non-donor-specific in eight patients (anti-MICA non-DSA, sera 8, 11, 12, 15, 18, 19, 22 and 24) (Figure 3A) . We did not find significant differences in either eGFR at Month 3 post-transplantation (51.09 ± 23.02 mL/ min/1.73 m 2 in anti-MICA DSA versus 42.14 ± 19.99 mL/ min/1.73 m 2 in anti-MICA non-DSA, P = 0.409) or days to reach optimal creatinine (79.67 ± 23.04 in DSA versus 80.13 ± 22.43 in non-DSA, P = 0.967); however, more patients with anti-MICA DSA also had anti-HLA antibodies versus patients with anti-MICA non-DSA (55 versus 38%, respectively).
Supereplet profile of preformed anti-MICA antibodies Duquesnoy et al. [17] classified a total of 11 anti-MICA specificities into two reaction groups by developing an eplet-based version of the HLAMatchmaker algorithm: CMGWS supereplet included anti-MICA*001, *002, *007, *012, *015, *017 and *018 specificities and AYVE supereplet contained anti-MICA*004, *009, *019 and *027 specificities (this last one showing the same amino acid sequence in the extracellular domain as MICA*008) [18] . Among our MICA + patients, 52% had anti-MICA specificities that included both CMGWS and AYVE supereplets ( Figure 3A ). All HLA + MICA + patients (n = 12) had specificities directed against CMGWS, but only half had specificities against both CMGWS and AYVE supereplets. Twelve of 13 HLA − MICA + patients had anti-CMGWS reactivity, and 6 of them also had anti-AYVE reactivity. Figure 3C ). Finally, every individual AYVE supereplet specificity reacted with significantly more intensity in HLA + MICA + than that in HLA − MICA + patients ( Figure 3D ). Regarding CMGWS supereplet, only anti-MICA*002 and anti-MICA*015 antibodies were significantly more intense in double-immunized versus HLA − MICA + patients (P = 0.005 and P = 0.020, respectively).
Preformed anti-MICA antibodies may bind native MICA antigens on cell surfaces We tested by FC if anti-MICA antibodies were able to bind MICA antigens on cell surfaces in addition to binding MICA molecules captured on microbeads, which may show conformational differences versus native MICA. Two MICA*008 homozygous cells were chosen (Hela and PMA/CD28-T-cell blasts) to improve the sensitivity of the binding assay, since MICA*008-positive cells express 7-to 10-fold higher levels of MICA proteins at the cell surface [19] . Reactions due to the presence of anti-HLA antibodies were avoided by performing FC with six anti-MICA*027/*008-positive pre-transplantation sera samples from HLA Because we observed that anti-MICA antibodies accompanied by anti-HLA antibodies showed stronger reactions, we selected two pre-transplant sera from the HLA + MICA + group with anti-MICA antibody screening >150 000 SFI (sera 3 and 4) to test their binding capacity to MICA native proteins. The anti-MICA*027/*008 reaction was strong for serum 3 (SFI 120 604) and weak for serum 4 (SFI 30 348). After absorption with lymphocyte pools, an intense decrease of most anti-HLA antibodies in both sera 3 and 4 was observed. Anti-HLA specificities corresponding to HeLa HLA-A68, -B72 and -Cw12 and to T blasts HLA-A3, -A11, -B27, -B52, -Cw7 and -Cw14 were virtually absent ( Figure 4A Figure 4D ) versus induced MICA antigen in PMA/CD28-T-blasts (85% MICApositive cells, MFI: 3.91, Figure 4F ) may explain differences in binding intensity of serum 3 between both cell lines and indicates that FC with HeLa cells is probably a more sensitive assay for the detection of specific anti-MICA*027 antibodies. HLA-absorbed serum 3 contained a small amount of anti-HLA-DRB1*13 antibodies (SFI 41 142) that bind neither HeLa cells, due to the lack of HLA class II on their membranes, nor T blasts, which expressed HLA-DR1 and -DR15 after PMA/ CD28 activation. Thus we conclude that preformed anti-MICA antibodies may bind native MICA proteins on cells membranes.
Preformed anti-MICA antibodies bind C1q and activate CDC The C1q Luminex assay uses microbeads exclusively covered by individual MICA antigens. We studied 13 positive anti-MICA single-antigen pre-transplant samples, all 9 anti-MICA DSA sera (2, 3, 5, 6, 9, 13, 14, 16 and 17; Figure 3A ) plus 4 samples from anti-MICA non-DSA recipients with a rejection event recorded and/or C4d + kidney biopsy (sera 4, 8, 20 and 25; Figure 3A) . Among the 13 sera, 10 were anti-MICA specific C1q negative (SFI values between 0 and 143) and 3 (23%) had C1q-fixing anti-MICA antibodies (SFI serum 3: 355 550; serum 4: 69 631; serum 17: 45 578). Interestingly, whereas anti-MICA antibodies were polyspecific in all three sera and recognized MICA antigens included in both CMGWS and AYVE 
C y t o t o x i c a n t i -M I C A a n t i b o d i e s i n t r a n s p l a n t antibodies are able to recognize membrane MICA antigens and to fix C1q.
Finally, we analysed the absorbed serum 3 in a modified CDC-AHG assay. Whereas all PMA/CD28-T-cell blasts incubated with negative control plus complement remained alive and all cells died when incubated with positive control plus complement, ∼60-80% of cells died after incubation with serum 3 and complement ( Figure 6A-C) . We conclude that preformed anti-MICA antibodies in the serum of transplant recipients are able to bind native MICA antigens on cell surfaces and activate classical complement cascade leading to target-cell death.
D I S C U S S I O N
We previously reported that preformed anti-MICA antibodies increase the risk for rejection and enhance the deleterious effect of PRA + status in the early post-transplantation period [10] . Here we provide further evidence that preformed anti-MICA antibodies deteriorate renal graft function after transplantation by showing that the time to reach optimal serum creatinine level after transplantation is longer for patients with pre-transplant anti-HLA and anti-MICA antibodies and, 3 months posttransplant, eGFR is the lowest in these patients. PRA + MICA + recipients showed the highest risk for CKD5T, which frequently involves retransplantation. Nevertheless, a limitation of our work exists, since results explaining the main and synergistic effects of anti-MICA antibodies are not fully consistent and partially depend on observations from a small cohort of patients (PRA + MICA + ). In our series, PRA + status included both anti-HLA DSA and non-DSA. Although anti-HLA DSA have the greatest impact on allograft evolution [20, 21] , a deleterious effect of anti-HLA non-DSA has also been reported [22] [23] [24] . Finally, systematic follow-up biopsies in patients with anti-MICA antibodies would help to further understand their potential role in worsening graft function.
From our initial cohort of 52 anti-MICA-sensitized patients as shown by the screening Luminex assay, 25 sera remained positive when analysed by the anti-MICA LSA. This reduction could be related to low strength of preformed anti-MICA antibodies together with bead-dependent dilutional effects (2 groups of beads bearing MICA antigens in the screening versus 11 groups in LSA) [25] . All recorded specificities corresponded to either one or both CMGWS and AYVE MICA [17, 18] . A higher frequency of preformed anti-MICA antibodies directed against anti-CMGWS than anti-AYVE supereplet was observed, and in particular against antigens MICA*001, *018 and *017. These specificities are also more prevalent in patients after kidney transplantation [18] . However, MICA*001, *018 and *017 are not the most frequent MICA antigens in Spanish or other related Caucasian populations, where MICA*008 (25% in Spanish population, included in AYVE supereplet), followed by *002, *004, *001, *009, *016 and *010, are mainly found [26] [27] [28] . Consequently the most frequent sensitizing events correspond to subjects bearing AYVE MICA antigens exposed to CMGWS alloantigens.
We observed that preformed anti-MICA antibodies are more intense when accompanied by anti-HLA antibodies, and this was especially noticed for anti-AYVE antibodies recognizing the most prevalent antigen MICA*027/*008. This suggests that the generation of anti-MICA*027/*008 antibodies corresponds mainly to an anti-allogeneic humoral immune response. These results support data from the study by Tonnerre et al. who observed that MICA*008 protein expresses 7-to 10-fold higher levels at the endothelial cell surface and is the preferential antigen leading to anti-MICA sensitization after renal transplantation in MICA-mismatched donor/recipient pairs [19] .
By using the C1q Luminex assay, we show for the first time that some preformed anti-MICA antibodies may bind complement. From an analysis of 13 pre-transplant sera, 3 were C1q-positive: sera 3 and 4 corresponded to third kidney recipients and serum 17 corresponded to a female with past pregnancies. This further supports the existence of an allogeneic response against MICA antigens. This low proportion is in contrast with data from post-transplant anti-MICA antibodies that showed 8 C1q-positive out of 10 analysed sera (unpublished data). It is possible that complement-binding IgG1, IgG3 and IgM may principally arise after transplantation, whereas pre-transplant antibodies may correspond to non-complement-binding subclasses. However, we noticed that anti-MICA antibody SFI was superior in post-versus pre-transplant samples, supporting the notion that positivity in the C1q Luminex assay is more frequent in sera with higher antibody titres [29, 30] . Interestingly, we observed that the highest C1q-positive SFI corresponded to anti-MICA*008, further supporting the immunogenicity of MICA*008 antigen and its role in the alloimmune response.
The capacity of anti-MICA antibodies to bind MICA antigens and trigger cell death in the presence of complement has been observed in the past. However, our data include two main novelties. First, we provide evidence that complement-mediated cell death is a capacity of anti-MICA antibodies existing in the serum of patients before transplantation, whereas previous authors have demonstrated the complement-mediated cytotoxicity capacity for post-transplant anti-MICA antibodies from patients rejecting kidney [5, 13] or heart [14] grafts or for anti-MICA*008 monoclonal antibodies generated in mice [13] . Second, we demonstrate cell death in CDC assays by incubating pre-transplant serum with mitogen-stimulated MICA-expressing T cells instead of the MICA-transfected or endothelial cell lines used in previous works. In our hands, contrary to data from Zou et al. [13] , CDC was negative with HeLa cells, maybe because the anti-MICA antibody titre in pre-transplant serum was not high enough to overcome protection from death mediated by membrane-bound complement regulators. Interestingly, CDC-positive serum 3 corresponded to an anti-MICA DSA-positive patient with suspected acute rejection, who responded to treatment with steroids. Studies are needed to understand the significance of positive MICA cross-matches in the clinical setting.
CO N C L U S I O N
In conclusion, we demonstrate that complement-mediated cytotoxicity is a property of some preformed anti-MICA antibodies. This capacity may play a role in deterioration of the renal allograft function early after transplantation in pretransplant anti MICA-sensitized recipients. The relative contribution of this mechanism to renal graft disfunction, compared with others such as NKG2D-mediated activation of NK cells by MICA-expressing renal grafts, cannot be definitively established yet. MICA-specific cross-matching and CDC tests with higher sensitivity may help to answer this question. 
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